Physician profile
Alan Noon
NPI 1467851212
$539.24
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $34.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.30 | 2021-2022 | |
| Glaxosmithkline, LLC. | $60.20 | 2021 | |
| Lilly USA, LLC | $48.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.82 | 2021 | |
| Eisai INC. | $33.12 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.85 | 2021 | |
| Amgen INC. | $31.83 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.65 | 2021 | |
| Novo Nordisk INC | $16.74 | 2021 | |
| Astellas Pharma US INC | $15.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.86 | 2021 | |
| Nabriva Therapeutics, Plc | $13.05 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $11.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Noon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.